O11 biomedical
Key Facts
| Invested since | 2023 |
| Based in | North Rhine-Westphalia |
About the company
O11 biomedical, a visionary medical technology start-up that emerged as part of BioTex at RWTH Aachen University/ University Hospital Aachen 2022, aims to improve survival rates and quality of life for patients struggling with severe respiratory distress. O11 has developed a disruptive therapy that allows patients to “breathe out” carbon dioxide via the intestines, freeing them from hours of agonizing ventilation therapy: RESPILIQ™. With currently 6 employees and its own production and development facility in Aachen, O11 is ideally positioned for the future.
Do you want to
know more about this company?
O11 biomedical in the news
Zum Artikel
Breathing through the gut: MedTech startup O11 biomedical secures EIC Accelerator Grant and seed funding to accelerate growth.
More startups from Life Sciences
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge …
To the complete profileof SciRhom
inContAlert was founded in September 2022 within the ecosystem of the University of Bayreuth. The MedTech startup’s sensor system empowers patients with neurogenic bladder dysfunction to manage their bladder on …
To the complete profileof inContAlert
Nia Health is a spin-off of the Charité Universitätsmedizin Berlin. The start-up develops a clinical diagnosis and therapy system for the continuous digital support of patients with chronic skin conditions. …
To the complete profileof Nia Health
oncgnostics develops – based on proprietary epigenetic biomarkers – highly reliable molecular in-vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in oncology.
To the complete profileof oncgnostics
Argá Medtech, developing the next generation Cardiac Ablation system for the treatment of Atrial Fibrillation and other arrhythmias. A safer, simpler, faster and more effective procedure for the benefit of …
To the complete profileof Argá Medtech
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
To the complete profileof Draupnir Bio
Exit
KINAXO supports pharmaceutical companies in the development of targeted drugs and predictive biomarkers for personalized healthcare. Exit since Feb. 2011. Purchaser: Evotec AG
To the complete profileof KINAXO
Exit
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …
To the complete profileof KSK Diagnostics
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
CorTec is a young medical engineering company focusing on innovations in the field of neurotechnology. With CorTec Brain Interchange we are developing a direct interface between brain and technology.
To the complete profileof CorTec
smartbax is developing a new generation of antibiotics to address the increasing spread of multidrug-resistant bacteria. Their team of experts works on innovative solutions focusing on substances that simultaneously address …
To the complete profileof smartbax
stimOS develops and markets (r)evolutionary technologies that functionalize implant materials and offers these technologies to implant manufacturers. With the product lines spineFuse and smartDENT the company develops own biosimilar implant …
To the complete profileof stimOS